PEDIATRIC INTERNATIONAL ADHERENCE QUESTIONNAIRE Behavior/Identification

NIAID PEDIATRIC AIDS CLINI	ICAL TRIALS GROUP Page	1 of 6
	e of Patient mmm dd yyy	y y
Protocol Number P0 0 0 0	Institution Code	
Form Week * Seq. No. ** Step	No. Key Operator Code	
* Enter a "1" if this is the first of this form for this date. Designate **Enter the subject's current study step number. Enter '1' if the st	e subsequent forms on same date with a 2, 3, etc tudy does not have multiple steps.	
The purpose of this questionnaire is to collect data which medication therapy actually taken within the last 3 days in a phase of a study protocol. In order to have confidence in the process through which these data are collected has been Please read and observe the following directions.	order to examine drug effect during the anal he data that will be collected with this instrur standardized.	yšis nent, the
Who administers? Any member of the professional clin out other ACTG study forms.	·	•
Who is questioned? The study participant, if the study participant if the study participant is primary caregiver prescribed drugs at home). If the appropriate respondent is a particular study visit when this form is scheduled, the for assessment omitted.	articipant has assumed responsibility for his/ the person responsible for administering the strain the primary caregiver and she/he is not prome should be marked as such (below) and the	her own ne esent for ne
How is the questionnaire administered? The question prompts) which should be read as stated, item after item, for study participant education should occur; any necessar place after the questionnaire is completed.	until the assessment is completed. No inter ry or additional education or counseling shou	ruptions uld take
The accuracy of self report is very good if the attitude of the form has introductory statements to set this tone. However elicited by the survey, what interaction happens after the quattitude of the clinical response, the manner in which inform behavioral counseling will absolutely influence future valid characteristics of therapeutic relationships and strive to adstudy participants.	questionnaire is completed is critically import mation is subsequently corrected, and the na dity. It is imperative that clinical teams reviev	ant. The ature of v the
QUESTIONS 1 - 3 ARE TO BE COMPLETED BY THE S	STUDY NURSE:	
 Was the questionnaire completed at this visit? If Yes, go to question 2. If No, complete 'a' and STOP. 	(1-Yes, 2-No)	
a. Indicate the reason the questionnaire was not comp	11-Study participant refused 12-Primary caregiver refused 13-Study participant missed clinic visi 14-There was not enough time 15-Primary caregiver not available	t
If Other, specify [30]:		
2. Who responded to the questions?	13-Biological father 18-Stepmother 14-Grandmother 19-Stepfather 15-Grandfather 99-Other specify	
If Other, specify [30]:	_	
3. Who is responsible for administering the medications?	12-Study participant solely responsible 13-Study participant and caregiver jointly 14-Study participant and other individual	
If Other, specify [30]:	99-Other, specify	

	PEDIATI	RIC INTERN	ATIONAL A	ADHERE	NCE (QUESTIC	ONNAIRE		I	Page 2 of 6
Pt. N	lo. [* Seq. No	o. **	Step N	0.	Date			
							mı	mm	dd	уууу
IN:	INSTRUCTIONS FOR COMPLETION OF MEDICATION TABLE Output Outpu									
		Columns A-D: Prior to the study visit, the study nurse should fill in the information in these columns for which adherence information is being collected as specified by the protocol.						fied		
•	Column A:	List the modication name								
•	Column B:	List the e	(if known or, if double-blinded study, record as marked on bottle). List the eight digit drug code for the drug listed in Column A. Refer to Appendix 3 or by using the Drug Code Lookup Program at the DMC Web Site (www.fstrf.org). List the drug color, type (blue pill, pink liquid, etc.) and note any special identifying label List the expected number of doses per 24 hour period. This refers to the schedule (e.g. 3 times per day, 4 times per day) and not the number of pills. Particulars of times per day)							
•	Column C: Column D:	List the d	rug color, typ	pe (blue p	ill, pink	liquid, etc	and note	any sp	ecial ider	ntifying labels
•	Column D.	schedule	e (e.g. 3 time	es per day	/, 4 time	es per day	/) and not	the nun	nber of pi	lls.
•	Columns E-I:	recorded as 3 lines per day).								
4.	MEDICATION	I LIST TABLE:	Do not ke	y Colum	n C.					
		cation Codes				² Doses Mi				
	1-Volunteered without prompt 2-Volunteered with prompt 3-Acknowledged when reminded 4-Did not acknowledge									
	Co	mplete Prior to	Visit			Complet	e During I	nterview	y	
	Α	В	С	D	Е	F	G	Н	<u>l</u>	
							Dos	es Misse	ed ²	
			Drug Color							
Dru	g Name(s) [30]:	Drug Code [8]:	Drug Color, Type and Labels	Expected # Doses	ID Code ¹	Reported # Doses	Yesterday	2 days ago	3 days ago	
Dru	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code ¹		Yesterday	_		
Dru a.	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code ¹		Yesterday	_		
	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code ¹		Yesterday	_		
	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code ¹		Yesterday	_		
a. b.	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code ¹		Yesterday	_		
a.	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code¹		Yesterday	_		
a. b.	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code¹		Yesterday	_		
a. b. c.	g Name(s) [30]:	Drug Code [8]:	Type and		ID Code¹		Yesterday	_		
a. b. c.	When was the of any of thes If Never ,		/your baby/y	# Doses	Code ¹	# Doses	1-Neve 2-Durin 3-Durin 4-Over	ago	ago	eeks

PEDIATRIC INTERNATIONAL ADHERENCE QUESTIONNAIRE Page 3 of 6						
Pt. No. *Seq. No. **	Step No.	Date mm	m dd	ууууу		
INSTRUCTIONS FOR COMPLETION OF MEDICATION SPECIFIC TABLE: • Enter the drug code of each medication that the study participant is receiving in the space provided at the top of each column. Problems Giving/Taking Medications: READ the following paragraph to the study participant or primary caregiver: "Many people at one time or another have trouble with these medications. We would like to better understand the things that make giving medications hard for families. These are some of the reasons others have identified which have made it difficult to take [give] all of the medications." Show and read the list of reasons to the study participant or primary caregiver. After the list is read, ask the following question for each medication: "Have any of the following been problems with giving/taking						
For data entry, use the tab key after the last entry on the page. Frequency Codes						
Enter Drug Code and Name: Drug Code Drug Code Drug Code Drug Code Drug Code Drug Code [8]: [8]: [8]:						
Drug #1 Name DO NOT KEY [30]:	Drug #2 Name [30]:	Drug #3 Name [30]:	Drug #4 Name [30]:	Drug #5 Name [30]:		
7. Problem identified? (1-Yes, 2-No)						
a. I ran out of medicine; didn't come for medicine						
b. The medicine tastes bad						
c. I just forgot						
d. I was worried about the side effects						
e. There was a change in daily routine						
f. Too busy with the baby/child						

	PEDIATRIC INTERNATIONAL	ADHERE	NCE QUEST	IONNAIRE		Page 4 of 6
Pt. N	No. * Seq. 1	No. **	Step No.	Date		
				mm	m dd	уууу
	Frequency Codes Use these codes to indicate how often the listed reason makes it harder to take (give) each of the medications the study participant is taking. 0-Never 1-(1-2) times per month 2-(1-2) times per week 3-(≥ 3) times per week					
	•	Drug Code]:	Drug Code [8]:	Drug Code [8]:	Drug Code [8]:	Drug Code [8]:
	DO NOT KEY [30	ug #1 Name 0]:	Drug #2 Name [30]:	Drug #3 Name [30]:	Drug #4 Name [30]:	Drug #5 Name [30]:
g.	My baby/child refused to take medicine or spat it out	. 🔲				
h.	There are lots of people looking after the baby/child and I am not always with him/her at the right time					
i.	I did not want others to notice me giving the medicine					
j.	My baby/child was ill					
k.	Don't think baby/child needs it anymore	e 🗌				
l.	Family said someone told them not to give/take the medicine					
m.	I was ill					
n.	I felt the medicine might be harmful to my baby/child					
0.	The baby/child was not staying in the house where the medicine was kept					
p.	I felt depressed					

QL5030(P0000)/00-00-00

PEDIATRIC INTERNATIONAL ADHERENCE QUESTIONNAIRE Page 5 of					
Pt. No * \$6	eq. No. **	Step No.	Date		
			mm	m dd	уууу
	Ise these codes o take (give) ead	to indicate how th of the medicat 0-Never 1-(1-2) tii 2-(1-2) tii			
Enter Drug Code and Name (Refer to last page for Drug Codes)	-	Drug Code [8]:	Drug Code [8]:	Drug Code [8]:	Drug Code [8]:
DO NOT KEY	Drug #1 Name [30]:	Drug #2 Name [30]:	Drug #3 Name [30]:	Drug #4 Name [30]:	Drug #5 Nam [30]:
q. My baby/child was well					
r. There was too much medicine to g	ive				
s. I was away from home					
t. I was busy with other things					
u. Other, specify					
Country: Enter 'SA' in the country box for Enter 'T' in the country box for Language: Enter 'E' if the scripts were rea Enter 'A' if the scripts were rea Enter 'Z' if the scripts were rea Enter 'So' if the scripts were rea Enter 'T' if the scripts were rea Enter 'T' if the scripts were rea	Thailand. ad to the study pad to the study	articipant in Afril articipant in Xhos articipant in Zulu participant in So	kaans. sa. tho.	Language:	
10-15-04 Date	Form Keyed (DC	NOT KEY):	/	/	_

PEDIATRIC INTERNATIONAL ADHERENCE QUESTIONNAIRE

DRUG CODE REFERENCE

Drug Codes and Names for Commonly Used Drugs.
Refer to Appendix 3 or the Drug Code Lookup Program at the
DMC Web Site (http://www.fstrf.org) for drugs not listed below.

	Anti-HIV Drugs					
08180407	Abacavir/ABC/Ziagen/1592U89	08180043	Indinavir/IDV/Crixivan			
08180025	Alovudine/CL-184824	10920013	Interleukin-2/IL-2			
08181205	Amprenavir/APV/Agenerase/141W94/VX-479	08180026	Lamivudine/3TC/Epivir			
08181214	Atazanavir/ATV/BMS-232632	08181218	Lexiva/Fosamprenavir/GW433908			
08180018	Atevirdine mesylate U-87201E	08181208	Lopinavir/Ritonavir (LPV/RTV)/Kaletra/			
08180006	Azidouridine/AzdU/azido-2',3'-dideoxyuridine		ABT-378/r			
08180021	AZT/ZDV/Zidovudine/Retrovir	08180048	Loviride/Lotrene			
08180032	CD4/RST4	08181204	Nelfinavir/NFV/Viracept			
08180412	Combivir (3TC/ZDV)	08180013	Nevirapine/NVP/Viramune			
08180024	d4T/Stavudine/Zerit´	08181203	Ritonavir/RTV/Norvir			
08180052	d4T XR/Zerit XR	08181209	Saquinavir soft gel/FTV/Fortovase			
08180414	DAPD/Amdoxovir/trimeric	08180030	Saquinavir (HGČ)/SQV/Invirase/R031-8959			
08180020	ddC/Zalcitabine/HIVID	08188804	T-20/pentafuside/Enfuvirtide/ENF			
08180007	ddl/Didanosine/Videx	08182002	TDF/Tenofovir/Tenofovir disoproxil			
08180051	ddl EC/Didanosine/Videx EC		fumarate/Viread			
08180031	DLV/delavirdine mesylate/Rescriptor	08180418	Trizivir (3TC/ABC/ZDV)			
08180804	Efavirenz/EFV/Sustiva/DMP266/Stocrin	99999998	Blinded Study Drug			
08180411	Fluorouridine/935U83	99999999	Drug Code Pending			
08180415	FTC/Emtriva/emtricitabine					